Biotinidase Activity Test

Your body depends on biotin (vitamin B7) to run four enzymes that process fat, sugar, and protein. But biotin does not last forever inside your cells. After each use, it gets locked onto leftover protein fragments, and a dedicated recycling enzyme must cut it free so it can be used again. That recycling enzyme is biotinidase. If your biotinidase activity is low, biotin gets trapped, your cells slowly starve for it, and the downstream damage can be severe.

The consequences of missing this enzyme range from seizures and hearing loss to skin rashes and vision damage. The good news: the fix is as simple as taking a daily biotin supplement. The catch: once symptoms like hearing loss or optic nerve damage appear, they are often permanent even after treatment starts. That makes early detection the entire game.

What Biotinidase Does

Biotinidase (the full technical name for this enzyme) is produced throughout your body, including in your liver, brain, kidneys, and blood. Its job is to free biotin from a bound form called biocytin (biotin attached to the amino acid lysine) so that the vitamin can be recycled and reattached to the four carboxylase enzymes that depend on it. Those carboxylases handle tasks your metabolism cannot skip: converting food into usable energy, building fats, and clearing certain amino acid byproducts.

When biotinidase works properly, you recycle enough biotin from food and internal turnover that dietary intake alone keeps your system running. When the enzyme is absent or sluggish, free biotin drops, carboxylase activity stalls, and toxic metabolic intermediates begin to build up. The damage shows up first in the brain and skin, the two tissues most sensitive to biotin shortfall.

Biotinidase Deficiency: Two Severity Levels

Biotinidase deficiency is an inherited condition caused by mutations in the BTD gene on chromosome 3. It follows an autosomal recessive pattern, meaning you need two copies of a faulty gene (one from each parent) to be affected. Carriers with one copy typically have around 50% of normal enzyme activity and show no symptoms.

The condition comes in two forms, defined by how much enzyme activity remains compared to the normal average:

• Profound deficiency: less than 10% of mean normal activity. Without treatment, this typically causes symptoms between one week and ten years of age, with a mean onset around 3.5 months.
• Partial deficiency: 10% to 30% of mean normal activity. People with partial deficiency may remain symptom-free for years and develop problems only during periods of metabolic stress such as illness or infection.

Neurological Damage

The brain is the most vulnerable organ when biotinidase is missing. In a systematic review of 1,113 individuals with biotinidase deficiency, neurological symptoms appeared in 67.2% of symptomatic cases. Seizures are the most common initial symptom, followed by low muscle tone (hypotonia), poor coordination (ataxia), and developmental delay. In adolescents and adults diagnosed late, the presentation often mimics multiple sclerosis, with damage to the spinal cord (myelopathy) and optic nerves.

Hearing loss affects about 26.9% of symptomatic cases and is typically permanent even after biotin treatment begins. Vision loss from optic nerve damage (optic atrophy) occurs in 34.4% and is similarly difficult to reverse. This is why early detection matters so much: treatment before symptoms appear prevents all of these outcomes.

Skin and Respiratory Signs

Skin problems appear in about 53.7% of symptomatic cases and can include eczema-like rashes, hair loss (alopecia), and recurrent yeast infections (candidiasis). Respiratory symptoms, including unusual breathing patterns and airway narrowing (laryngeal stridor), occur in 17.8% of cases. These signs often appear alongside or just before neurological symptoms, and they can be the first visible clue that something is wrong.

Reference Ranges

Biotinidase activity is reported either as an absolute measurement (in nanomoles per minute per milliliter of serum) or as a percentage of the mean normal value. The percentage format is preferred because it allows comparison across different lab methods. Each lab should establish its own reference values, so always compare your results within the same laboratory over time.

For reference, the mean normal activity in healthy adults is 7.57 ± 1.41 nmol/min/mL. Obligate carriers (parents of an affected child who each carry one mutation) average about 3.49 nmol/min/mL, which is roughly 46% of normal. Newborns normally have 50% to 70% of adult values, which rise over the first days to weeks of life.

Who Gets Tested

All U.S. newborn screening programs and more than 30 countries now include biotinidase deficiency in their newborn screening panels, making this one of the most widely screened inherited metabolic conditions. The combined incidence of profound and partial deficiency is about 1 in 61,000 births worldwide, though this varies significantly by population. In Brazil's Minas Gerais region, incidence reaches 1 in 13,909. Hispanic populations, Turkish, Saudi Arabian, and Emirati populations also show higher rates, often linked to higher rates of marriage between relatives.

Beyond newborn screening, testing is appropriate for anyone showing unexplained seizures, developmental delay, skin rashes with hair loss, hearing loss, or vision changes, particularly when standard workups have not provided answers. About 5.2% of biotinidase deficiency cases are diagnosed through family screening of siblings of an affected child. If a family member has been diagnosed, all siblings should be tested regardless of whether they have symptoms.

When Results Can Be Misleading

Sample handling is the single biggest source of false results. Biotinidase is sensitive to heat and humidity, and specimens exposed to warm temperatures during shipping or storage will show artificially low enzyme activity. Together with prematurity, sample mishandling accounts for the majority of false-positive newborn screening results.

Premature birth temporarily lowers biotinidase activity and drives roughly half of all false-positive newborn screens. Liver dysfunction can also reduce enzyme levels without indicating an inherited deficiency. Elevated bilirubin (common in jaundiced newborns) has been reported to affect results as well. Season matters too: one study found that samples collected in summer averaged 20 millireflectance units lower than winter samples, and winter samples averaged 17 units higher, likely because of heat exposure during transport.

On the medication side, sulfa drugs cause falsely elevated activity readings, which is especially dangerous because a true deficiency could be masked. Ampicillin, hemoglobin (from a hemolyzed sample, meaning red blood cells broke during collection), and glutathione can also interfere with the assay. Blood transfusions complicate interpretation because transfused blood carries variable amounts of donor biotinidase whose activity fades unpredictably over time.

The Importance of Control Samples

The American College of Medical Genetics and Genomics (ACMG) strongly recommends that every diagnostic biotinidase test be run alongside a sample from an unrelated healthy individual and, when possible, both parents. This might sound unusual, but there are documented cases where children were misdiagnosed with profound deficiency by reputable laboratories simply because control samples were not included. Those children received unnecessary biotin treatment for years before repeat testing with proper controls showed normal enzyme function.

When enzyme results fall in an ambiguous range, molecular genetic testing of the BTD gene can settle the question definitively. Some states and countries now perform DNA analysis routinely on all newly diagnosed infants as part of confirmatory testing.

Tracking Your Trend

A single biotinidase measurement can mislead you. One study comparing consecutive samples from the same patients found that the biochemical classification changed in 50% of cases between the first and second blood draw. Age, prematurity, and jaundice all contributed to this variability. The study's authors concluded that a diagnosis of biotinidase deficiency should never rest on a single measurement.

For individuals identified through newborn screening, a confirmatory test on a new sample is standard practice. For those with partial deficiency, retesting around age 5 is recommended, since about 48% of people with partial deficiency show enzyme activity recovery with age. In 20% of those cases, the recovery is enough to consider adjusting or stopping biotin supplementation. If you have a confirmed diagnosis, regular follow-up with a metabolic specialist ensures your treatment remains appropriate as your enzyme activity may shift over time.

For adults being tested for the first time because of unexplained neurological or dermatological symptoms, get a baseline, confirm any abnormal result with a repeat test that includes parental and unrelated control samples, and pursue genetic testing if the enzyme result is ambiguous.